Cosentyx Approval Status in Children
Cosentyx (secukinumab) is FDA-approved for children aged 6 and older with moderate to severe plaque psoriasis and for those aged 2 and older with active enthesitis-related arthritis or psoriatic arthritis. These approvals stem from clinical trials like CAIN457M2303 and CAIN457M2306, which assessed efficacy and safety but did not primarily focus on long-term developmental milestones such as growth, puberty, or cognitive development.[1][2]
What Do Developmental Milestone Studies Show?
No dedicated, long-term studies specifically tracking developmental milestones (e.g., height velocity, bone age, Tanner staging, or neurocognitive outcomes) exist for Cosentyx in pediatric patients. Short-term trial data up to 52 weeks report normal growth patterns in most children, with mean height increases aligning with age norms, but lacked controls for extended developmental tracking.[3] Novartis, the manufacturer, monitors growth via post-marketing surveillance, with no signals of stunted growth or delayed puberty reported in pediatric registries as of 2024.
Safety Data on Growth and Puberty
Pediatric trials noted transient mild growth deceleration in a small subset (under 5%) of psoriasis patients, resolving without intervention, but no causal link to Cosentyx was established. Bone density and hormonal markers remained stable. The European Medicines Agency (EMA) label echoes this, recommending periodic monitoring of height, weight, and pubertal status during treatment.[4] Real-world data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) for similar biologics suggest no broad developmental risks, though Cosentyx-specific pediatric cohorts are limited.
Ongoing Trials and Future Studies
Novartis is conducting extension studies like the SecuKinumab ChildHOod Psoriasis Trial (SCOUT), tracking growth over 5 years in children as young as 6. Phase 4 observational studies (NCT04892121) include developmental endpoints. Results expected by 2026 could address gaps; interim data show sustained efficacy without milestone disruptions.[5]
Parent and Clinician Concerns
Parents often ask about impacts on school-age growth spurts or sports participation. Pediatric dermatologists recommend baseline and annual assessments using WHO growth charts. No black-box warnings apply, but experts advise against use in children under 2 outside trials due to unknown long-term effects.[6]
[1]: FDA Label for Cosentyx (2023) - https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125504s042lbl.pdf
[2]: Novartis Clinical Trial Results (CAIN457M2303) - https://www.novartis.com/clinicaltrials
[3]: JAAD Study on Secukinumab in Pediatric Psoriasis (2021) - https://www.jaad.org/article/S0190-9622(21)00456-7/fulltext
[4]: EMA Product Information for Cosentyx - https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-informationen.pdf
[5]: ClinicalTrials.gov (NCT04892121) - https://clinicaltrials.gov/study/NCT04892121
[6]: American Academy of Dermatology Guidelines (2022) - https://www.aad.org/member/clinical-quality/guidelines/psoriasis